liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH
Department of Endocrinology and Reproductive Medicine, GH Pitié Salpêtrière, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Université Paris VI Pierre et Marie Curie.
Department of Endocrinology and Reproductive Medicine, GH Pitié Salpêtrière, Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Université Paris VI Pierre et Marie Curie.
Pfizer Limited, Sandwich, Kent, UK.
Pfizer, New York, New York, USA.
Show others and affiliations
2009 (English)In: European Journal of Endocrinology, ISSN 0804-4643, E-ISSN 1479-683X, Vol. 161, 533-540 p.Article in journal (Refereed) Published
Abstract [en]

Objective: Changes observed during adult GH deficiency (GHD) are most often reversed with the administration of recombinant human GH (rhGH). To avoid daily injections, a long-acting GH molecule has been obtained by covalent binding of polyethylene glycol (PEG) with rhGH (PEG–GH), allowing weekly s.c. injections. This study was designed to assess its efficacy and safety, in adult GHD subjects.

Design and methods: This was a randomized, double-blind, placebo-controlled, multiple-dose, parallel group study. Subjects were recruited from 34 centers. A total of 105 subjects with GHD were assigned a treatment. They received 6 weekly injections of either PEG–GH or placebo. Subjects were randomized into one out of four treatment groups (Groups A–D) or placebo (Group E). Groups A, B, and C received 1, 3, and 4 mg PEG–GH respectively, for the first 3 weeks followed by 2, 6, and 8 mg PEG–GH respectively, for the remaining 3 weeks. Group D received 4 mg PEG–GH for 6 weeks. Group E received placebo. The study was suspended because of the development of lipoatrophy in certain subjects and restarted with an injection rotation plan, before being terminated due to further subjects developing lipoatrophy.

Results: A total of 13 cases of injection-site lipoatrophy were reported, of which ten were in females and three occurred after the first injection; all cases were independent of PEG–GH dose or IGF1 levels, either basal or under treatment.

Conclusion: The unpredictable occurrence of injection-site lipoatrophy with weekly long-acting pegylated GH molecules may be a limiting factor for their development.

Place, publisher, year, edition, pages
2009. Vol. 161, 533-540 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-52313DOI: 10.1530/EJE-09-0422OAI: oai:DiVA.org:liu-52313DiVA: diva2:281311
Available from: 2009-12-15 Created: 2009-12-15 Last updated: 2017-12-12

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Ekman, Bertil

Search in DiVA

By author/editor
Ekman, Bertil
By organisation
Internal Medicine Department of Endocrinology and Gastroenterology UHLFaculty of Health Sciences
In the same journal
European Journal of Endocrinology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 86 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf